Summary of Study ST001925
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001215. The data can be accessed directly via it's Project DOI: 10.21228/M8NQ5X This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
Study ID | ST001925 |
Study Title | MS Untargeted Metabolomics from Human Serum |
Study Summary | Multiple Myeloma patients were treated with the proteasome inhibitor carfilzomib in different protocols according to their clinical stage. Paired serum samples were obtained before i.v injection and after 1-8h post treatment and snap frozen. Samples were stored at -80°C until analysis. |
Institute | University of Zurich |
Last Name | Mendez |
First Name | Max |
Address | Rorschacherstrasse 95. 9007, St.Gallen |
maxmendez@runbox.com | |
Phone | +41 71 494 10 67 |
Submit Date | 2021-09-21 |
Num Groups | 2 |
Total Subjects | 6 |
Num Males | 5 |
Num Females | 1 |
Raw Data Available | Yes |
Raw Data File Type(s) | raw(Waters) |
Analysis Type Detail | LC-MS |
Release Date | 2022-01-02 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Treatment:
Treatment ID: | TR002015 |
Treatment Summary: | See attached file |
Treatment Compound: | Carfilzomib i.v |
Treatment Route: | i.v |
Treatment Dose: | As described in attached file |